The US investment grade corporate bond market has seen some exceptional transactions since the beginning of the year, but everyone (including the underwriters) was taken aback by the size and scope of the $16 billion six-tranche Yankee offering brought by Swiss healthcare and pharmaceutical firm Roche on February 18.

Lots of records were broken by this deal. It was easily the largest dollar deal ever, beating the $11bn three-tranche effort by General Electric Capital Corporation in 2002, and was

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

If you already have an account, please sign in here.


Want to know what’s included in our free registration? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here